Tag: chronic pain
SynerFuse announces presentation of IDE proof-of-concept study data
SynerFuse has announced that Michael Park (University of Minnesota, Minneapolis, USA)—principal investigator for the company’s investigational device exemption (IDE) proof-of-concept study—presented data from the study’s...
Nevro announces US FDA approval of HFX iQ system to personalise...
Nevro Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS)...
Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes
A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
Current gaps and barriers in patient access to spinal cord stimulation
Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors that currently present difficulties...
High-frequency SCS takes the stage to relieve chronic pain from diabetic...
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic...
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...
New study offers hope for recovered motor function in patients with...
Researchers report the successful use of a novel therapeutic strategy to enhance forelimb recovery in mice with chronically injured spinal cords. The findings were...
Non-opioid alternative for chronic pain approved in Europe
A Conformité Européene (CE) Mark has been received by Medtronic for its neurostimulation platform Intellis for spinal cord stimulation (SCS) and peripheral nerve stimulation...
US FDA clears Stimwave’s full-body MRI-ready wireless peripheral nerve stimulator
Stimwave has received US Food and Drug Administration (FDA) 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI...
CE mark approval for Stimwave’s world-first fully percutaneous spinal cord stimulator...
CE mark approval has been granted for the world’s first percutaneous injectable anchor system, SandShark. The Stimwave system is used to fixate the company’s...
Tackling opioid addiction in America
Substance misuse is “one of the most pressing public health crises of our time” according to US Surgeon General Vivek H Murthy, in his...
Report details plethora of serious health problems faced by spinal cord...
Paralysis is just one of the many serious health problems faced by patients who suffer spinal cord injuries, according to a report according to...
Spinal cord stimulation reduces or stabilises opioid use among chronic pain...
New research has found spinal cord stimulation therapy can reduce or stabilise the use of opioids in patients battling chronic pain. Researchers examined opioid...
Survey indicates that many back pain patients get limited relief from...
Millions of people take opioids for chronic back pain, but many of them get limited relief while experiencing side effects and worrying about the...
AMA president issues opioid epidemic guidance US physicians
The president of the American Medical Association—Steven J Stack—has issued an open letter to US physicians about the country’s opioid epidemic.
Entitled, “Confronting a crisis:...